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Background: Prevention or attenuation of diabetic vascular complications includes anti-hypertensive treatment
with renin-angiotensin system inhibitors on account of their protective effects beyond blood pressure reduction.
The present study aimed to investigate the effects of telmisartan, an angiotensin II type 1 receptor blocker (ARB), on
blood pressure, aortic stiffening, and aortic remodelling in experimental type 1 diabetes in rats.
Methods: Diabetes was induced by streptozotocin (STZ) (65 mg/kg) in male Wistar rats. One diabetic group was
treated for 10 weeks with telmisartan (10 mg/kg/day p/o). Pressure-independent aortic pulse wave velocity (PWV)
was measured under anaesthesia after intravenous infusion of phenylephrine and nitroglycerine. Aortic wall samples
were collected for histomorphometrical analysis.
Results: Untreated diabetes imposed differential effects on aortic stiffening, as demonstrated by increased isobaric
PWV over a range of high blood pressures, but not at lower blood pressures. This was associated with loss and
disruption of elastin fibres and an increase in collagen fibres in the aortic media. Treatment with telmisartan
decreased resting blood pressure, reduced aortic stiffness, and partially prevented the degradation of elastin
network within the aortic wall.
Conclusions: Telmisartan improved the structural and functional indices of aortic stiffening induced by untreated
STZ-diabetes, demonstrating the importance of ARBs in the therapeutic approach to diabetic vascular complications.
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Diabetes mellitus (DM) is a major cardiovascular (CV) risk
factor, as evidenced by three-fold higher risk of developing
CV complications in patients with DM [1]. Functional and
structural changes in the large arteries are an important
contributor to high mortality in the diabetic population
[2]. Metabolic abnormalities associated with DM impair
the integrity of elastic fibres in the arterial wall which
translates into increased stiffness of the wall material. The
accumulation of advanced glycation end-products (AGEs)
is a major pathogenic mechanism contributing to arterial* Correspondence: erik.salum@gmail.com
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unless otherwise stated.stiffening in DM [3]. Assessment of arterial stiffness by
measuring pulse wave velocity (PWV) is a well-established
method and large-scale studies have demonstrated its utility
in predicting the CV risk and outcome in general popula-
tion [4] and in high-risk conditions, including hypertension
[5], end-stage renal disease [6], and DM [7,4].
The renin-angiotensin system (RAS) has an important
role in the regulation of arterial structure and function.
Angiotensin II (Ang II) induces vasoconstriction and has
been shown to contribute to vascular wall remodelling [8]
via non-haemodynamic mechanisms such as stimulation of
vascular smooth muscle proliferation and rearrangements
of elastin and collagen fibres [9]. The renin-angiotensin sys-
tem activity in vascular tissue is known to be increased
under hyperglycaemic conditions [10], promoting vascular
hypertrophy and wall stiffness.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Salum et al. Diabetology & Metabolic Syndrome 2014, 6:57 Page 2 of 10
http://www.dmsjournal.com/content/6/1/57Blockade of RAS with either angiotensin-converting en-
zyme inhibitors or Ang II type 1 receptor blockers (ARBs)
has been reported to improve CV outcomes and reduce
the risk of micro- and macrovascular complications of
DM [11-13]. Furthermore, clinical studies have demon-
strated that while RAS blockers are equally effective in
blood pressure (BP) reduction, they may be superior to
other antihypertensive agents in reducing the risk of CV
events in patients with DM [13,14]. It is suggested that the
protective effects of RAS blockers on the vasculature are,
at least in part, due to reduction in the adaptive remodel-
ling and stiffness of the arterial wall independently on
their BP lowering effects.
Among ARBs, telmisartan has exhibited beneficial meta-
bolic effects by increasing insulin sensitivity [15] and im-
proving plasma lipid profile [16]. These properties indicate
that telmisartan may provide unique possibilities for the
prevention and treatment of DM and its vascular compli-
cations [17].
Previously, we have demonstrated that treatment with
vitamin D improves aortic wall remodelling induced by
short-term uncontrolled experimental DM, but does not
limit the development of aortic stiffening assessed by PWV
under pressure-independent conditions [18]. The aim of
the present study was to examine the hypothesis that
telmisartan would attenuate the development of diabetes-
induced aortic remodelling, and that this would be associ-
ated with reduction in aortic stiffness independently on BP.
Materials and methods
Animals
Male Wistar rats (RccHan:WIST, n = 40, age 3 weeks)
were purchased from Harlan Laboratories (Harlan Labora-
tories, Inc., The Netherlands). Before entering the experi-
ments, the animals were allowed to acclimatise for at least
one week in the animal facility. All animals were kept in a
room with controlled temperature (21 ± 2°C) and lighting
(12:12-h light–dark cycle) with free access to food pellets
and tap water. All experimental procedures were approved
by the Estonian National Board of Animal Experiments
and were conducted in accordance with the Directive
2010/63/EU of the European Parliament.
Experimental protocol
Rats were randomly assigned to three groups: control
(n = 10), untreated diabetic (n = 15), and telmisartan-
treated diabetic (n = 15) group. Intraperitoneal injection
of streptozotocin (STZ) 65 mg/kg (Sigma-Aldrich,
St. Louis, MO, USA), freshly dissolved in 0.9% saline,
was used to induce diabetes. After 48 hours, blood glu-
cose was measured in samples taken from the tail vein,
using a glucometer (Glucocard X-meter, Arkray Inc.,
Japan). Rats were considered diabetic if the blood glucose
was >15 mmol/L. Treatment with telmisartan (BoehringerIngelheim International GmbH, Germany) was started im-
mediately after confirmation of diabetes. Telmisartan
(10 mg/kg per day) was administered by gavage, dissolved
in drinking water, for 10 weeks. Telmisartan was stopped
one day prior to measurement of the haemodynamic pa-
rameters. Weekly, body weights were recorded for all
groups and glycosuria was assessed with reagent strips
(Combur Test, Roche, Germany) to exclude ketosis in rats
with diabetes.Haemodynamic measurements
The animals were anaesthetised with a mixture of fentanyl
(0.07 mg/kg, Gedeon-Richter Plc., Hungary), midazolam
(5 mg/kg, Roche Pharma AG, Germany), and ketamine
(75 mg/kg Vetoquinol Biowet Sp. z.o.o., Poland) adminis-
tered subcutaneously. The optimal concentrations of the
anaesthetic substances had been determined in previous ex-
periments [18]. The depth of anaesthesia was monitored
regularly by assessing the reflex response to noxious stimuli
(hindpaw pinch) or tactile stimuli (corneal stroking). After
induction of anaesthesia, animals were placed on a heating
pad and body temperature was maintained at 37°C.
A 2.5 F high-fidelity, dual pressure sensor catheter with
50 mm separation between sensors (SPC-721, Millar In-
struments Inc., TX, USA) was soaked in a water bath for
30 minutes to allow stability of the baseline before balan-
cing and calibration against a mercury sphygmomanom-
eter. The catheter was then introduced via the femoral
artery into the descending aortic trunk so that the distal
sensor was positioned at the beginning of the descending
aorta and the resulting position of the proximal sensor was
just proximal to the aortic bifurcation. The positioning of
the distal sensor in the thoracic aorta was confirmed by
the appearance of the dicrotic notch on the pressure wave-
form. The rats were allowed to stabilise before resting
blood pressures were recorded. Mean arterial pressure
(MAP) was determined from measurements made by the
proximal pressure transducer. Mean arterial pressure was
increased and decreased by infusion of phenylephrine (PE)
(50 μg/min) and nitroglycerine (NTG) (30 μg/min), re-
spectively, via a catheter inserted into the femoral vein.
Each drug was infused until the BP plateaued. Between the
infusions, the rats were allowed a stabilisation period of at
least 5 minutes and subsequent infusion of the opposing
substance was given after the BP had returned to baseline.
Pulse pressure waves were recorded simultaneously at the
two aortic sites and PWV was calculated offline by dividing
the propagation distance by propagation time using an au-
tomated foot-to-foot method [18,19]. Data were acquired
at a sampling rate of 2 kHz (PowerLab, ADInstruments,
Australia) and feature extraction and calculations made
with custom scripts in Spike2 v.6. software (Cambridge
Electronic Design, United Kingdom).
Table 1 Model 1: linear; Model 2: second order
polynomial; Model 3: third order polynomial fit
Df AIC
Model 1 5.00 970.37
Model 2 6.00 786.11
Model 3 7.00 787.55
A second order polynomial provides the best fit to the grouped data.
Df, degrees of freedom; AIC, Akaike information criterion.
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After completion of haemodynamic measurements, rats
were euthanised by cardiac puncture and cervical dis-
location. Urine samples were obtained, drawn directly
from the urinary bladder. Glucose concentration in the
urine was measured by a colorimetric hexokinase glucose-
6-phosphate dehydrogenase method (Glucose-HK kit,
Spinreact, Spain).
Histological analysis and morphometric parameters
Samples for histology were fixed in 10% formalin for
12 hours and embedded in paraffin with vacuum infiltration
processor (Tissue-Tek® VIP™ 5 Jr, Sakura, USA). Specimens
were cut with microtome Ergostar HM 200 (Microm,
Germany) to 4 μm thick sections and stained using
resorcin-fuchsin (Roth, Germany) and haematoxylin-eosin
(Fisher Diagnostics, USA). The histological slides were ex-
amined under Olympus BX50 (Japan) light microscope.
Estimation of the internal diameter of the aorta was per-
formed by measuring two inner diameters at right angle for
each cross-section of the thoracic aorta. At least four differ-
ent cross-sections of the aorta were analysed for each rat.
Thickness of the medial layer of the aorta was determined
in the thoracic aorta cross-sections by ten consecutive mea-
surements in a systematic manner to evaluate all segments
of the circumference of the aorta. At least four different
cross-sections of aorta were analysed for each rat.
The staining intensity of elastin and collagen fibres in
the media was evaluated by a subjective scale ranging from
0 to 3 (0 – no staining of fibres, 1 – poor staining of fibres,
2 – moderate staining of fibres, 3 – intensive staining of fi-
bres). Evaluations were performed by two independent ob-
servers in a blinded fashion; the scores were summed and
used for statistical analysis.
Immunohistochemistry
Three-μm thick paraffin sections mounted on poly-L-
lysine coated SuperFrost slides (Menzel-Gläser, Germany)
were deparaffinised and rehydrated. Peroxidase activity
was blocked by 0.6% H2O2 (Merck, Germany) in methanol
(Merck, Germany). Then the sections were washed in tap
water and in PBS (pH = 7.4; Gibco, Invitrogen, USA) for
10 min, treated with normal 1.5% goat serum (Gibco, Invi-
trogen Corporation, USA) for 20 min at room temperature
and incubated with the primary antibody anti-carboxymethyl
lysine (mouse monoclonal antibody [CML26], abcam, UK)
diluted 1:50 overnight at 4°C in the humidity chamber. On
the next day, the sections were incubated with the biotinyl-
ated horse anti-mouse secondary antibody for 30 min at
room temperature. After a wash step the sections were incu-
bated with the avidin-biotin peroxidase complex ELITE sys-
tem (Vectastain Elite ABC Kit, Vector Laboratories Inc.,
Burlingame, USA) for 30 minutes. Peroxidatic activity was
detected with 3,3′-Diaminobenzidine (Vector LaboratoriesInc., USA) and the sections were counterstained with
hemalaun, dehydrated and mounted with DPX (Fluka,
Switzerland). The labeling was expressed on a subjective
scale ranging from 0 to 4 (0 – no staining, 1 – weak stain-
ing, 2 – moderate staining, 3 - strong staining, 4 – very
strong staining). Two independent observers in a blinded
fashion performed the evaluation. The scores were summed
and used for statistical analysis (Mann–Whitney U-test).
Immunohistochemistry negative controls were performed
by omitting primary antibody (mouse IgG was used in place
of the primary antibody).
Statistical analysis
All haemodynamic parameters were averaged into 5 mmHg
MAP bins. Analysis was restricted to the MAP range of 60
to 185 mmHg. Rat S11 and S12 were merged to create one
sample, due to lack of data in each rat. Rat S14 was re-
moved due to lack of data. Second order polynomials were
fitted using least squares regression to each individual rat
data set, a second order polynomial being confirmed as a
better fit than either linear or third order polynomial by
Akaike’s “An Information Criterion (AIC)” (Table 1). The
intercepts (a) and coefficients (b, c) were extracted from
the polynomial model (Equation 1), and comparison be-
tween groups made by analysis of variance (ANOVA),
using a post-hoc, Bonferroni corrected t-tests to ascertain
differences.
PWV ¼ a þ b  MAP þ c  MAP2 ð1Þ
MAP2 ¼ MAP2 ð2Þ
For analysis of the data as a whole, one of two methods
was employed. (1) The data was transformed into a linear
form (Equation 2) and analysis of covariance (ANCOVA)
was used if the assumption of equal slopes was maintained.
(2) If the assumption of equal slopes was not maintained,
robust analysis ANCOVA [20] was employed with com-
parison of groups at 60, 90, 120, 150, and 180 mmHg
MAP and a 20% trimmed mean. The robust analysis
ANCOVA accommodates non-linearity, heteroscedasticity,
and unequal slopes. The assumption of equal slopes was
tested by ANCOVA as in (Equation 1) with an interaction
term between PWV and MAP, and PWV and MAP2. If ei-
ther interaction was significant, showing that slopes were
not equal, method (Equation 2) was employed.
Table 2 Basic and laboratory parameters
Group Body weight (g) Heart weight (mg) Cardiac index (%) Urine glucose (mmol/L)
Before After
Control 130 ± 10 408 ± 24 950 ± 90 2.32 ± 0.22 1.6 ± 0.9
Diabetes 135 ± 12 216 ± 59* 620 ± 130* 2.79 ± 0.25¶ 511.6 ± 97.2*#
Diabetes + telmisartan 135 ± 14 254 ± 62* 670 ± 120* 2.67 ± 0.35¶ 424.9 ± 63.5*
Body weight was assessed at the beginning and at the end of the experiment.
¶P <0.05 vs Control; *P <0.001 vs Control; #P <0.05 vs Diabetes + telmisartan.
Cardiac index = heart weight (mg)/body weight (g).
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means ± standard deviation (SD). Differences between
the groups were evaluated using the one-way ANOVA
followed by Tukey’s post-hoc analysis for multiple compar-
isons of group means. Semi-quantitative data were com-
pared by the Kruskal-Wallis one-way ANOVA followed by
Mann–Whitney U test. Differences were considered to be
statistically significant when P was <0.05. Statistical com-
parisons were performed with the Statistica software (ver-
sion 8; StatSoft, USA) and with the software R (version
2.15.3 for Windows; The R Foundation for Statistical
Computing, Austria).Results
Basic and biochemical parameters
The initial body weights were similar in all groups
(Table 2). In the course of the experiment, rats in both
treated and untreated diabetic groups presented with ab-
normalities associated with persistent hyperglycaemia, i.e.,
hyperphagia, polydipsia, polyuria, and wasting of stored
fat as evidenced by retarded weight gain. The final body
weights were significantly lower in the diabetic groups
compared to the control group, while no difference was
observed between the treated and untreated diabetic
groups. The ratio of heart weight to body weight as a sur-
rogate index of cardiac hypertrophy was significantly in-
creased in both diabetic groups, compared to the control
group. Glucose concentration in the urine samples was
significantly higher in both diabetic groups, compared to
the control group. Treatment with telmisartan resulted in
slight but statistically significant reduction in urinary glu-
cose excretion (Table 2).Table 3 Resting anaesthetised haemodynamic parameters ob
Group SBP DBP MAP
(mmHg) (mmHg) (mmHg)
Control 155 ± 15# 113 ± 15# 130 ± 28#
Diabetes 142 ± 13# 105 ± 13# 124 ± 14#
Diabetes + telmisartan 110 ± 14 75 ± 14 92 ± 12
SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial press
time; PWV, pulse wave velocity.
*P <0.01 vs Control; #P <0.01 vs Diabetes + telmisartan.Haemodynamic parameters
Prior to administration of vasoactive substances, resting
systolic blood pressure (SBP), diastolic blood pressure
(DBP), pulse pressure, MAP, heart rate (HR), PWV, and
maximal change in blood pressure (dP/dt) were recorded
(Table 3). There were no differences in blood pressures be-
tween the control and untreated diabetic group, but SBP,
DBP, and MAP were significantly lower in the telmisartan-
treated group. HR was decreased in both diabetic groups,
and further reduced by treatment with telmisartan, most
likely due to lower resting MAP. Peak dP/dt, a surrogate
index of left ventricular systolic function, was significantly
decreased in the untreated diabetic rats and partially at-
tenuated by telmisartan, compared to the control rats. As
a result of significantly lower resting MAP in the telmisar-
tan group, PWV was also significantly lower in that group
with no differences between the control and untreated
diabetic group.
The means and standard deviations of coefficients of the
second order polynomial curve fits to individual rats in
PWV= a + b ×MAP+ c ×MAP2 are provided in Table 4
and polynomial curves are presented in Figure 1. ANOVA
on the intercepts and coefficients is provided in Table 5.
There was no significant difference in the intercept (a) be-
tween the groups, but there were significant differences in
the coefficients (b) and (c) between the untreated diabetics
and controls, but not among the other groups (Tables 6, 7,
and 8).
Table 5 gives an ANCOVA with interaction terms for
MAP and Group, and MAP2 and group. It shows that
there was a significant interaction between MAP and
group (P <0.001) but not MAP2 and group (P = 0.21). As
there was a significant interaction term, and slopestained before the administration of vasoactive substances
PP HR Peak dP/dt PWV
(mmHg) (beats/min) (mmHg/s) (m/s)
41 ± 3 462 ± 46 4024 ± 617 4.5 ± 0.5#
38 ± 9 386 ± 48*# 2186 ± 198*# 4.6 ± 0.9#
35 ± 5 321 ± 26* 3294 ± 183* 3.6 ± 0.3
ure; PP, pulse pressure; HR, heart rate; dP/dt, maximal change in pressure over
Table 4 Means and standard deviations of coefficients of
the second order polynomial curve fits to individual rats







Control 3.8 ± 0.9 −0.02 ± 0.02 0.00023 ± 0.00009
Diabetes 6.0 ± 2.1 −0.07 ± 0.04* 0.00045 ± 0.00018*
Diabetes + telmisartan 5.1 ± 1.5 −0.05 ± 0.03 0.00038 ± 0.00014
*P <0.05, Bonferroni adjusted unpaired t-test. SD, standard deviation; MAP,
mean arterial pressure.
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test between group differences. This showed differences
between untreated diabetes and control groups at all levels
other than 60, 100, and 110 mmHg MAP (Table 6). Un-
treated diabetes and treated diabetes groups differed at all
MAP levels other than 60, 110, 120, 130, and 150 mmHg
(Table 7). Controls were not significantly different to
treated animals at any MAP value (Table 8).
Aortic wall morphology and histomorphometry
The lumen diameter of the thoracic aorta was significantly
smaller in the untreated diabetic group compared to the
control and telmisartan groups (Table 9). The width of the
medial layer was decreased both in the untreated diabetic
and telmisartan-treated groups compared to the control
group (Table 9, Figure 2). The staining intensity of medial
elastic fibres in the untreated diabetic group was de-
creased compared to the control group, but in the telmi-
sartan group the staining of elastic fibres did not differ
significantly from the controls (Table 9). Furthermore,
focal irregularities in the arrangement of elastic fibres were
noted in the untreated diabetic group that were not ob-
served in the telmisartan group (Figure 3). Even more pro-
nounced differences were seen in the staining of collagen
fibres in the medial layer as higher collagen concentrationsFigure 1 A second order polynomial fitted on PWV-MAP curve, with t
the untreated diabetes group over the high pressure range, compared to t
the treated and control groups across the full MAP range. MAP, mean arterwere present in the untreated diabetes group compared to
the control group (Table 9, Figure 3). This resulted in sig-
nificantly lower medial ratio of elastin to collagen in the
untreated diabetic group (Table 9). Although elastin to
collagen ratio tended to increase in the telmisartan group
it still remained lower than that in the control group
(Table 9). No differences between groups were seen in the
count of nuclei of smooth muscle cells (Table 9).
Immunohistochemical detection of CML demonstrated
strong immunostaining in the aortas of the untreated dia-
betes group with the strongest staining in the intima and
adventitia. Staining was moderate in the telmisartan-
treated group and weak in the control group (Figure 4,
Table 9). Staining was not seen in the negative controls
where the primary antibody was omitted.
Discussion
In the present study, we have examined the association be-
tween structural (geometry and composition) and func-
tional (stiffness, blood pressure) changes in the aortic wall
and the protective effects of the ARB, telmisartan, in STZ-
diabetic rats. We have demonstrated that treatment with
telmisartan limits diabetes-induced aortic stiffening and
improves the structural integrity of elastic fibres within
the aortic wall.
Our finding of increased aortic wall stiffness following
10 weeks of untreated hyperglycaemia extends our previ-
ous study demonstrating that blood pressure-independent
aortic stiffening is established early in the course of DM
and is not associated with elevated resting BP [18]. In the
current study, were able to reproduce similar DM-induced
vascular changes in significantly younger animals (4 months
vs 4 weeks at the induction of DM), thus eliminating the
possible influence of aging on arterial remodelling.
Pharmacological modulation of BP allows character-
isation of aortic stiffness, as measured by PWV, underhe 95% confidence interval shaded. PWV is significantly higher in
he treated and control groups. No differences were observed among
ial pressure.
Table 5 Analysis of covariance with an interaction term
between MAP and group, and MAP2 and group
Df Sum Sq Mean Sq F value P value
MAP 1 849.91 849.91 3953.44 <0.001
MAP2 1 47.35 47.35 220.27 <0.001
Group 2 13.41 6.70 31.18 <0.001
MAP:Group 2 5.58 2.79 12.97 <0.001
MAP2:Group 2 0.67 0.34 1.56 0.2
Residuals 571 122.75 0.21
MAP, mean arterial pressure; Df, degrees of freedom; Sum Sq, sum of squares;
Mean Sq, mean of squares.
Significant interaction between group and MAP indicates that the slopes of
different groups are significantly different.
Table 7 Robust method analysis of covariance, diabetes
(D) vs diabetes + telmisartan (DT)
MAP n1 n2 DIF TEST SE CI.low CI.hi P value crit.val
60 10 21 0.12 0.98 0.12 −0.38 0.62 0.36 4.12
70 21 35 0.19 3.95 0.05 0.04 0.34 <0.001 3.10
80 28 40 0.21 4.51 0.05 0.07 0.36 <0.001 3.07
90 32 43 0.23 3.98 0.06 0.06 0.41 <0.001 3.01
100 36 45 0.16 2.08 0.08 −0.07 0.40 0.04 3.01
110 38 44 0.11 1.07 0.11 −0.20 0.43 0.29 2.99
120 39 42 0.16 1.43 0.11 −0.17 0.48 0.16 2.99
130 38 40 0.25 2.01 0.12 −0.12 0.62 0.05 3.00
140 39 40 0.36 2.13 0.17 −0.15 0.86 0.04 3.00
150 38 39 0.35 1.70 0.21 −0.27 0.98 0.10 3.02
160 38 33 0.53 2.37 0.22 −0.15 1.21 0.02 3.03
170 35 21 0.88 3.80 0.23 0.17 1.58 <0.001 3.06
MAP, mean arterial pressure; SE, standard error; CI, confidence interval.
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consider, because BP exerts a great influence on PWV,
and its physiological variations occur rapidly and fre-
quently. Non-linear relationship between PWV and MAP
was established by fitting a second-order polynomial func-
tion for the full range of experimentally controlled pres-
sures. Across the low pressure range, PWV-MAP curves
were similar between all groups, whereas at higher pres-
sures, noticeable differences between the slopes of the
curves were observed in different experimental groups.
Steeper PWV-MAP slope in the untreated diabetic group
most likely indicates increased aortic stiffness attributable
to intrinsic modifications within the aortic wall independ-
ent of BP. Furthermore, the absence of elevated BP in un-
treated diabetic rats assessed under resting conditions
gives additional support to the significance of underlying
morphological abnormalities. Earlier studies have also
shown that STZ-diabetic rats may be normotensive at the
early stage of the disease [21], while impaired large artery
properties may be detected as early as 8 weeks after induc-
tion of STZ-diabetes [22,23].Table 6 Robust method analysis of covariance, control (C)
vs diabetes (D)
MAP n1 n2 DIF TEST SE CI.low CI.hi P value crit.val
60 23 10 −0.13 1.04 0.13 −0.63 0.37 0.03 3.95
70 42 21 −0.18 3.65 0.05 −0.34 −0.03 <0.001 3.07
80 45 28 −0.17 3.64 0.05 −0.31 −0.03 <0.001 3.08
90 46 32 −0.15 2.94 0.05 −0.31 0.01 0.01 3.05
100 45 36 −0.11 1.98 0.06 −0.28 0.06 0.05 3.00
110 45 38 −0.12 1.50 0.08 −0.35 0.12 0.14 3.02
120 45 39 −0.18 1.91 0.09 −0.46 0.10 0.06 3.00
130 45 38 −0.26 2.33 0.11 −0.58 0.07 0.02 2.99
140 45 39 −0.35 2.22 0.16 −0.82 0.12 0.03 3.01
150 45 38 −0.44 2.15 0.20 −1.05 0.18 0.04 3.03
160 45 38 −0.55 2.50 0.22 −1.21 0.12 0.02 3.04
170 44 35 −0.72 3.20 0.23 −1.41 −0.03 0.001 3.05
MAP, mean arterial pressure; SE, standard error; CI, confidence interval.Functional properties of the aortic wall are determined
by the content of two major wall constituents, elastin and
collagen fibres, and their orderly arrangement. Elastin
fibre network is known to mediate the load at low distend-
ing pressures, while collagen fibres are gradually recruited
with increasing pressure [24]. In our study, significant re-
duction in the aortic content of elastin was observed in
the untreated diabetic group, paralleled by an increase in
collagen content, resulting in lower ratio of elastin to col-
lagen. These findings are concordant with the profile of
aortic stiffness in the untreated diabetic group. When BP
increases, loss of elastin and increase in collagen content
causes premature recruitment of stiffer collagen fibres as
demonstrated by higher isobaric PWV across high BP
range. Studies on the biomechanical properties of elastin
and collagen have shown that when elastase-digestedTable 8 Robust method analysis of covariance, diabetes +
telmisartan (DT) vs control (C)
MAP n1 n2 DIF TEST SE CI.low CI.hi P value crit.val
60 23 21 −0.01 0.20 0.06 −0.20 0.18 0.85 3.12
70 42 35 0.01 0.15 0.05 −0.13 0.14 0.88 3.00
80 45 40 0.05 1.34 0.03 −0.06 0.15 0.19 2.99
90 46 43 0.08 1.62 0.05 −0.06 0.22 0.11 2.99
100 45 45 0.05 0.69 0.08 −0.18 0.28 0.49 3.02
110 45 44 −0.00 0.04 0.09 −0.29 0.28 0.97 3.02
120 45 42 −0.02 0.21 0.10 −0.32 0.27 0.83 3.00
130 45 40 −0.01 0.06 0.12 −0.37 0.36 0.95 3.00
140 45 40 0.01 0.05 0.13 −0.40 0.41 0.96 3.00
150 45 39 −0.09 0.56 0.15 −0.54 0.37 0.57 2.99
160 45 33 −0.02 0.11 0.16 −0.49 0.45 0.92 3.00
170 44 21 0.15 0.90 0.17 −0.37 0.68 0.37 3.06
MAP, mean arterial pressure; SE, standard error; CI, confidence interval.
Table 9 Histomorphometric parameters of the
thoracic aortas




1.65 ± 0.18 1.23 ± 0.19¶ 1.54 ± 0.22#
Width of media (μm) 117.39 ± 16.30 82.62 ± 9.32¶ 87.68 ± 11.11¶
Elastic fibres in media
(arbitrary units)
2.84 ± 0.23 2.54 ± 0.34* 2.65 ± 0.27
Collagen fibres in
media (arbitrary units)
0.66 ± 0.19 1.43 ± 0.31¶ 1.30 ± 0.10¶
Elastin/collagen ratio
in media (%)
4.28 ± 0.57 1.79 ± 0.035¶ 2.07 ± 0.50*
Smooth muscle cell nuclei 78.86 ± 15.01 94.10 ± 21.12 89.17 ± 24.90
CML (arbitrary units) 0.53 ± 0.08 2.28 ± 1.05¶ 1.55 ± 0.80¶
Values are expressed as means ± SD. CML, Nε-(carboxymethyl) lysine.
*P <0.05 vs Control; ¶P <0.001 vs Control; #P <0.05 vs Diabetes.
Figure 2 Micrographs of the transverse sections in the control
group (A), untreated diabetic group (B), and diabetes + telmisartan
group (C). Note the decreased width of the medial layer in both
diabetic groups. Resorcin-fuchsin.
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http://www.dmsjournal.com/content/6/1/57arteries are stretched, collagen fibres are more rapidly en-
gaged, in contrast to smooth and gradual recruitment in
normal elastic arteries [25,26]. The transition point from
recruitment of elastin to collagen fibres could not be
mathematically determined in our study, but seems to be
around 110–120 mmHg, which is in agreement with an
earlier report by Armentano et al. [24].
Diabetes-induced arterial wall remodelling is a well-
established complication and characterised by thickening
of intimal and medial layers. Increased carotid artery
intima-media thickness has frequently been reported in
patients with type 1 DM [27,28] and is considered an in-
dependent CV risk factor [29]. In this regard, our find-
ings of reduced width of aortic media in the untreated
diabetic group are at variance with observations from
human studies. However, experimental studies with differ-
ent durations of STZ-diabetes have shown that at an early
stage, the width of the aortic medial layer may be de-
creased [30,31], and gradually increase with the ongoing
disease due to vascular smooth muscle cell proliferation
[32]. The structural alterations occurring during the course
of DM may involve differential transcriptional regulation of
matrix metalloproteinases [33] and transforming growth
factor-beta [34,35]. The accelerated formation of AGEs
driven by sustained hyperglycaemia also plays a critical role
in the pathogenesis of diabetic macrovascular complica-
tions [34,36]. Indeed, we have shown that the accumulation
of Nε-(carboxymethyl) lysine (CML), a major antigenic
structure among a variety of AGEs [37], in the aortic wall
is significantly enhanced in untreated DM [36] which was
also the case in the current study. Similarly to our previous
experiment we observed that CML was localised in all
layers of the aorta with prominent levels in the intima and
adventitia.
Telmisartan is an ARB with significant protective effects
against tissue remodelling, in addition to equipotent bloodpressure reducing effects, compared to other RAS in-
hibitors, captopril or losartan [38]. Telmisartan has been
reported to act as a partial agonist of peroxisome proliferator-
activated receptor-γ (PPAR-γ) [39], which is involved in the
regulation of carbohydrate and lipid metabolism [40]. Further-
more, there is increasing evidence that PPAR-γ agonists
exert anti-inflammatory, antioxidative, and antiproliferative
Figure 3 Representative micrographs of the wall of the rat aortas from the control group (a and d), untreated diabetes group (b and
e) and diabetes + telmisartan group (c and f). Decreased thickness of the medial layer was noted in both untreated diabetes and diabetes +
telmisartan group, while focal disorganisation of elastic lamellae were seen in untreated diabetes group (b). Resorcin-fuchsin (a-c) and van Gieson
(d-e). ▲ elastin lamellae are stained violet (resorcin-fuchsin). ● collagen fibres are stained red (van Gieson).
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http://www.dmsjournal.com/content/6/1/57effects on the vascular wall [40,41]. We report that treat-
ment of STZ-diabetic rats with telmisartan for 10 weeks
was able to attenuate the development of DM-induced aor-
tic stiffening in the context of improved structural proper-
ties of the aortic wall. Specifically, telmisartan preserved the
amount of elastin within the medial layer of the aorta, and
maintained the normal organisation of elastin network.
These effects were also associated with a modest, but insig-
nificant, increase in the ratio of elastin to collagen. The
anti-fibrotic effects of telmisartan were evident despite no
effect on glucose control or body weight. To our best of
knowledge, the current study is the first to report that theFigure 4 Immunohistochemical localisation of Nε-(carboxymethyl) lys
group (b) and diabetes + telmisartan group (c). Strong immunostaining
immunostaining was moderate in the in diabetes + telmisartan group (c), w
(a). Diaminobenzidine + hemalaun.ARB telmisartan modulates DM-induced aortic stiffening
and remodelling independently on BP reduction. Previous
studies have demonstrated that, in addition to direct in-
hibition of the pro-fibrotic effects of Ang II, treatment
with ARBs may have indirect pressure-independent pro-
tective effects by interfering with AGE formation via anti-
oxidative mechanisms [42]. We found that treatment with
telmisartan had a minor effect on reducing the accumula-
tion of CML in the aortic wall that may have been limited
by the pathological impact of hyperglycaemia. Miyata and
co-workers [42] demonstrated in vitro that ARBs are ef-
fective against AGE formation that has been confirmed inine in the rat aorta of control group (a), untreated diabetes
(brown colour) was found in the aortas of diabetes group (b), the
hile in the control group the staining intensity was weak
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http://www.dmsjournal.com/content/6/1/57experimental studies with murine type 2 DM models; how-
ever, to our best of knowledge, there is a lack of interven-
tional studies showing similar results in experimental type
1 DM models.
In summary, we have shown that the ARB telmisartan
prevents aortic stiffening associated with untreated STZ-
diabetes in the context of improved structural properties
of the aortic wall such as preservation of the concentration
and organisation of elastin network. The results from our
study provide further evidence that increased aortic stiff-
ness is an early phenomenon in the pathogenesis of DM
and its complications that is attributable to intrinsic modi-
fications within the aortic wall, and that the inhibition of
RAS has a specific role in the prevention of early DM-
induced vascular damage beyond BP lowering effects.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ES performed the experiments, participated in performing the statistical
analysis, and drafted the manuscript. MB and APA performed statistical
analysis, participated in the study design and coordination, and helped to
draft the manuscript. ES, PK, JK, MZ, JE conceived of the study, participated
in its design and coordination, and helped to draft the manuscript. MA and
AA performed the histological analyses and helped revising the manuscript.
All authors have read and approved the final manuscript.
Acknowledgment
This work was supported by the Institutional Research Fundings (IUT02-7
and IUT20-42) by the Estonian Ministry of Education and Science and by
Target Financing (No. 0180012 s11) by the European Union through the
European Regional Development Fund.
Author details
1Department of Cardiology, University of Tartu, 8 Puusepa Street, Tartu
51014, Estonia. 2Endothelial Centre, University of Tartu, 8 Puusepa Street,
Tartu 51014, Estonia. 3Department of Biochemistry, Centre of Excellence for
Translational Medicine, University of Tartu, 19 Ravila Street, Tartu 50411,
Estonia. 4The Australian School of Advanced Medicine, 2 Technology Place,
Macquarie University, Sydney, NSW 2109, Australia. 5Department of Vascular
Surgery, Tartu University Hospital, 8 Puusepa Street, Tartu 51014, Estonia.
6Department of Anatomy, University of Tartu, 19 Ravila Street, Tartu 50411,
Estonia. 7Institute of Veterinary Medicine and Animal Sciences, Estonian
University of Life Sciences, 62 Fr. Kreutzwaldi Street, Tartu 51014, Estonia.
Received: 28 November 2013 Accepted: 6 May 2014
Published: 20 May 2014
References
1. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors,
and 12-yr cardiovascular mortality for men screened in the Multiple Risk
Factor Intervention Trial. Diabetes Care 1993, 16:434–444.
2. Giannattasio C, Failla M, Grappiolo A, Gamba PL, Paleari F, Mancia G:
Progression of large artery structural and functional alterations in Type I
diabetes. Diabetologia 2001, 44:203–208.
3. Airaksinen KE, Salmela PI, Linnaluoto MK, Ikaheimo MJ, Ahola K, Ryhanen LJ:
Diminished arterial elasticity in diabetes: association with fluorescent
advanced glycosylation end products in collagen. Cardiovasc Res 1993,
27:942–945.
4. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML,
Schalekamp MA, Asmar R, Reneman RS, Hoeks AP, Breteler MM, Witteman
JC: Arterial stiffness and risk of coronary heart disease and stroke: the
Rotterdam Study. Circulation 2006, 113:657–663.
5. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P,
Benetos A: Aortic stiffness is an independent predictor of all-cause andcardiovascular mortality in hypertensive patients. Hypertension 2001,
37:1236–1241.
6. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: Impact
of aortic stiffness on survival in end-stage renal disease. Circulation 1999,
99:2434–2439.
7. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG: Aortic
pulse-wave velocity and its relationship to mortality in diabetes and
glucose intolerance: an integrated index of vascular function?
Circulation 2002, 106:2085–2090.
8. Dzau VJ, Gibbons GH, Pratt RE: Molecular mechanisms of vascular renin-
angiotensin system in myointimal hyperplasia. Hypertension 1991, 18:100–105.
9. Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, Korsgaard N,
Mulvany MJ, Lever AF: Angiotensin II causes vascular hypertrophy in part
by a non-pressor mechanism. Hypertension 1991, 17:626–635.
10. Miller JA: Impact of hyperglycemia on the renin angiotensin system in early
human type 1 diabetes mellitus. J Am Soc Nephrol 1999, 10:1778–1785.
11. Prospective UK: Diabetes Study Group: Efficacy of atenolol and captopril
in reducing risk of macrovascular and microvascular complications in
type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.
BMJ 1998, 317:713–720.
12. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH,
Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators:
Effects of losartan on renal and cardiovascular outcomes in patients
with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.
13. Heart Outcomes Prevention Evaluation Study Investigators: Effects of
ramipril on cardiovascular and microvascular outcomes in people with
diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy,
Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000,
355:253–259.
14. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U,
Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen
MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, LIFE Study Group:
Cardiovascular morbidity and mortality in patients with diabetes in the
Losartan Intervention For Endpoint reduction in hypertension study (LIFE):
a randomised trial against atenolol. Lancet 2002, 359:1004–1010.
15. Pershadsingh HA, Kurtz TW: Insulin-sensitizing effects of telmisartan:
implications for treating insulin-resistant hypertension and cardiovascular
disease. Diabetes Care 2004, 27:1015.
16. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R: Effects of
telmisartan compared with eprosartan on blood pressure control,
glucose metabolism and lipid profile in hypertensive, type 2 diabetic
patients: a randomized, double-blind, placebo-controlled 12-month
study. Hypertens Res 2004, 27:457–464.
17. Yamagishi S, Takeuchi M: Telmisartan is a promising cardiometabolic
sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses
2005, 64:476–478.
18. Salum E, Kampus P, Zilmer M, Eha J, Butlin M, Avolio AP, Põdramägi T,
Arend A, Aunapuu M, Kals J: Effect of vitamin D on aortic remodeling in
streptozotocin-induced diabetes. Cardiovasc Diabetol 2012, 11:58.
19. Ng K, Hildreth CM, Phillips JK, Avolio AP: Aortic stiffness is associated with
vascular calcification and remodeling in a chronic kidney disease rat
model. Am J Physiol Renal Physiol 2011, 300:1431–1436.
20. Wilcox RR: More regression methods. In Introduction to robust estimation
and hypothesis testing. 2nd edition. Burlington, MA, USA: Elsevier Academic
Press; 2005.
21. Hicks KK, Seifen E, Stimers JR, Kennedy RH: Effects of streptozotocin-
induced diabetes on heart rate, blood pressure and cardiac autonomic
nervous control. J Auton Nerv Syst 1998, 69:21–30.
22. Zhao JB, Lu X, Zhuang FY, Gregersen H: Biomechanical and morphometric
properties of the arterial wall referenced to the zero-stress state in
experimental diabetes. Biorheology 2000, 37:385–400.
23. Chang KC, Hsu KL, Tseng YZ: Effects of diabetes and gender on
mechanical properties of the arterial system in rats: aortic impedance
analysis. Exp Biol Med (Maywood) 2003, 228:70–78.
24. Armentano RL, Levenson J, Barra JG, Fischer EI, Breitbart GJ, Pichel RH,
Simon A: Assessment of elastin and collagen contribution to aortic
elasticity in conscious dogs. Am J Physiol 1991, 260:1870–1877.
25. Fonck E, Prod’hom G, Roy S, Augsburger L, Rufenacht DA, Stergiopulos N:
Effect of elastin degradation on carotid wall mechanics as assessed by a
constituent-based biomechanical model. Am J Physiol Heart Circ Physiol
2007, 292:2754–2763.
Salum et al. Diabetology & Metabolic Syndrome 2014, 6:57 Page 10 of 10
http://www.dmsjournal.com/content/6/1/5726. Kochova P, Kuncova J, Sviglerova J, Cimrman R, Miklikova M, Liska V,
Tonar Z: The contribution of vascular smooth muscle, elastin and
collagen on the passive mechanics of porcine carotid arteries.
Physiol Meas 2012, 33:1335–1351.
27. Frost D, Beischer W: Determinants of carotid artery wall thickening in
young patients with Type 1 diabetes mellitus. Diabet Med 1998,
15:851–857.
28. Yamasaki Y, Kawamori R, Matsushima H, Nishizawa H, Kodama M, Kajimoto Y,
Morishima T, Kamada T: Atherosclerosis in carotid artery of young IDDM
patients monitored by ultrasound high-resolution B-mode imaging.
Diabetes 1994, 43:634–639.
29. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi
G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A,
Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De
Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I,
Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, et al:
Guidelines for the management of arterial hypertension: The Task Force for
the Management of Arterial Hypertension of the European Society of
Hypertension (ESH) and of the European Society of Cardiology (ESC).
Eur Heart J 2007, 2007(28):1462–1536.
30. Searls Y, Smirnova IV, Vanhoose L, Fegley B, Loganathan R, Stehno-Bittel L:
Time-dependent alterations in rat macrovessels with type 1 diabetes.
Exp Diabetes Res 2012, 2012:278620.
31. Akgün-Dar K, Bolkent S, Yanardag R, Tunali S: Vanadyl sulfate protects
against streptozotocin-induced morphological and biochemical changes
in rat aorta. Cell Biochem Funct 2007, 25:603–609.
32. Fukuda G, Khan ZA, Barbin YP, Farhangkhoee H, Tilton RG, Chakrabarti S:
Endothelin-mediated remodeling in aortas of diabetic rats. Diabetes
Metab Res Rev 2005, 21:367–375.
33. Song W, Ergul A: Type-2 diabetes-induced changes in vascular extracellular
matrix gene expression: relation to vessel size. Cardiovasc Diabetol 2006, 5:3.
34. Rumble JR, Cooper ME, Soulis T, Cox A, Wu L, Youssef S, Jasik M, Jerums G,
Gilbert RE: Vascular hypertrophy in experimental diabetes. Role of
advanced glycation end products. J Clin Invest 1997, 99:1016–1027.
35. Kanzaki T, Shiina R, Saito Y, Zardi L, Morisaki N: Transforming growth
factor-beta receptor and fibronectin expressions in aortic smooth muscle
cells in diabetic rats. Diabetologia 1997, 40:383–391.
36. Salum E, Kals J, Kampus P, Salum T, Zilmer K, Aunapuu M, Arend A, Eha J,
Zilmer M: Vitamin D reduces deposition of advanced glycation end-
products in the aortic wall and systemic oxidative stress in diabetic rats.
Diabetes Res Clin Pract 2013, 100:243–249.
37. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW: N epsilon-(car-
boxymethyl) lysine is a dominant advanced glycation end product (AGE)
antigen in tissue proteins. Biochemistry 1995, 34:10872–10878.
38. Wagner J, Drab M, Bohlender J, Amann K, Wienen W, Ganten D: Effects of
AT1 receptor blockade on blood pressure and the renin-angiotensin
system in spontaneously hypertensive rats of the stroke prone strain.
Clin Exp Hypertens 1998, 20:205–221.
39. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M,
Qi N, Wang J, Avery MA, Kurtz TW: Identification of telmisartan as a
unique angiotensin II receptor antagonist with selective PPARgamma-
modulating activity. Hypertension 2004, 43:993–1002.
40. Takano H, Hasegawa H, Zou Y, Komuro I: Pleiotropic actions of PPAR
gamma activators thiazolidinediones in cardiovascular diseases.
Curr Pharm Des 2004, 10:2779–2786.
41. Marx N, Duez H, Fruchart J-C, Staels B: Peroxisome Proliferator-Activated
Receptors and Atherogenesis: Regulators of Gene Expression in Vascular
Cells. Circ Res 2004, 94:1168–1178.
42. Miyata T, Van Ypersele De Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H,
Ishikawa N, Nangaku M, Kurokawa K: Angiotensin II receptor antagonists
and angiotensin-converting enzyme inhibitors lower in vitro the formation
of advanced glycation end products: biochemical mechanisms. J Am Soc
Nephrol 2002, 13:2478–2487.
doi:10.1186/1758-5996-6-57
Cite this article as: Salum et al.: Angiotensin II receptor blocker
telmisartan attenuates aortic stiffening and remodelling
in STZ-diabetic rats. Diabetology & Metabolic Syndrome 2014 6:57.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
